Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087970 · ClinicalTrials.gov registry record · Phase 2
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 69
- Enrollment target
NCT01087970 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 69 participants.
The verdict
NCT01087970, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 69 participants
- Enrollment target
Study Summary
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Pemetrexed
- DRUG Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 69 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01087970
The ClinicalTrials.gov registry entry for NCT01087970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 69 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01087970 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01087970 about?
NCT01087970 is a clinical study titled "A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer". The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT01087970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 69 participants. The study started on 2010-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01087970?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Pemetrexed (DRUG), Cetuximab (DRUG).
Who is sponsoring clinical trial NCT01087970?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.